nivolumab + gemcitabine + tegafur-gimeracil-oteracil

The combination of nivolumab, gemcitabine, and tegafur-gimeracil-oteracil (S-1) is a chemo-immunotherapy regimen being investigated for the treatment of metastatic pancreatic adenocarcinoma. This therapeutic approach, often referred to as the NGS regimen in clinical trials led by the National Taiwan University Hospital, combines the PD-1 blocking monoclonal antibody nivolumab with a chemotherapy backbone of gemcitabine and S-1. The rationale for this combination is that initial chemotherapy with gemcitabine and S-1 (GS) can reduce tumor burden and potentially release neoantigens, thereby priming the immune system. Subsequent or concurrent administration of nivolumab aims to enhance the anti-tumor immune response by blocking the PD-1 receptor on T-cells, preventing its interaction with PD-L1/PD-L2 on tumor cells and overcoming immune suppression within the tumor microenvironment. This regimen is specifically targeted at patients with newly diagnosed Stage IV disease who demonstrate an initial response to chemotherapy.

Brand names

OpdivoGemzarTS-1TS1TS 1

Other names

Nivolumab + Gemcitabine + S-1Nivolumab + GS